Document Detail

Hepatis C virus genotype 4.
MedLine Citation:
PMID:  12897906     Owner:  NLM     Status:  MEDLINE    
Hepatitis C virus genotype 4 chronic hepatitis predominates in the Eastern Mediterranean region of the world. In the Kingdom of Saudi Arabia, as high as 62% of all cases are due to genotype 4. Results of efficacy and safety clinical trials using pegylated-interferon plus ribavirin for chronic hepatitis C patients have shown great promise, but treatment of early responders should be maintained at 180 mg of pegylated-interferon alfa-2a plus 1000-1200 mg of ribavirin for 48 weeks unlike the 24 weeks recommended for genotypes 2 and 3. Hepatitis C genotype 4 may not be as "difficult to treat" as initially thought.
Ossama A Shobokshi
Related Documents :
21064156 - Treatment of acute hepatitis c in human immunodeficiency virus-infected patients: the h...
11727306 - Recent advances in the discovery of small molecule therapies for hcv.
15346246 - Treatment of chronic hepatitis c infection with peginterferons plus ribavirin.
12897906 - Hepatis c virus genotype 4.
12894086 - Oral pemphigus vulgaris associated with hiv infection.
12856346 - An examination of hiv/aids patients who have excellent adherence to haart.
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Saudi medical journal     Volume:  24 Suppl 2     ISSN:  0379-5284     ISO Abbreviation:  Saudi Med J     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-08-04     Completed Date:  2004-09-22     Revised Date:  2008-06-23    
Medline Journal Info:
Nlm Unique ID:  7909441     Medline TA:  Saudi Med J     Country:  Saudi Arabia    
Other Details:
Languages:  eng     Pagination:  S79-80     Citation Subset:  IM    
King Faisal Specialist Hospital & Research Centre, MBC#31, PO Box 3354, Riyadh 11211, Kingdom of Saudi Arabia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Genome, Viral*
Hepacivirus / genetics*
Hepatitis C, Chronic / drug therapy*,  epidemiology,  genetics*
Interferon Alfa-2b / administration & dosage
Ribavirin / administration & dosage
Saudi Arabia / epidemiology
Treatment Outcome
Reg. No./Substance:
36791-04-5/Ribavirin; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chronic hepatitis C treatment. Side effects and their management.
Next Document:  Hepatitis C virus seroprevalence rate among Saudis.